Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.44
Change (%) Stock is Down 0.2 (2.31%)
Volume564,533
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
12/18/14Verastem Appoints Daniel Paterson as Chief Operating Officer
BOSTON--(BUSINESS WIRE)--Dec. 18, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Daniel Paterson, Chief Business Officer, has been appointed to the role of Chief Operating Officer, effective December 12, 2014. “On behalf of the Board of Directors and the entire management team, we wholeheartedly congratulate Dan on his promo... 
Printer Friendly Version
12/11/14Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium
BOSTON--(BUSINESS WIRE)--Dec. 11, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced a poster presentation at the 2014 San Antonio Breast Cancer Symposium (SABCS) taking place December 9 - 13, 2014. "The clinical relevance of cancer stem cells (CSCs) has perhaps been best documented in breast cancer,” said Jonathan Pachter, Ph.D., Ve... 
Printer Friendly Version
12/08/14Verastem Presents Data at the 2014 American Society of Hematology Annual Meeting
BOSTON--(BUSINESS WIRE)--Dec. 8, 2014-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced oral and poster presentations at the 2014 American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6 - 9, 2014, in San Francisco. “High risk B-ALL characterized by Ikaros mutation remains an unmet medical need with lim... 
Printer Friendly Version
12/04/14Verastem to Present Data at the 2014 San Antonio Breast Cancer Symposium
BOSTON--(BUSINESS WIRE)--Dec. 4, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced a scheduled poster presentation at the 2014 San Antonio Breast Cancer Symposium (SABCS) taking place December 9 - 13, 2014. Details for the poster presentation at SABCS are as follows: Title: VS-6063 (defactinib) and VS-4718 Reduce Cancer Stem Cells ... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.